Global ST2 Biomarker Market Overview
Western Market Research estimates that the Global ST2 Biomarker Market was valued at USD XXXX million in 2025 and is projected to reach USD XXXX million by 2036, growing at a CAGR of XX% during the forecast period 2026–2036.
ST2 (suppression of tumorigenicity 2) is a clinically validated cardiac biomarker used primarily for risk stratification, prognosis, and therapy monitoring in heart failure. Unlike natriuretic peptides, ST2 levels are less affected by age, body mass index, or renal function, making it a valuable adjunct marker in cardiovascular diagnostics. Market growth is driven by rising heart-failure prevalence, expanding adoption of precision diagnostics, increasing biomarker-guided therapy, and broader availability of automated immunoassays.
This study integrates primary research (clinical laboratories, cardiologists, diagnostic manufacturers) with secondary analysis (clinical guidelines, regulatory pathways, and historical market data). The assessment evaluates assay performance, automation trends, reimbursement dynamics, and regional adoption patterns.
Impact of COVID-19 on the ST2 Biomarker Market
The COVID-19 pandemic temporarily disrupted routine diagnostics; however, the ST2 biomarker market demonstrated resilience due to:
-
Increased cardiovascular risk assessment in hospitalized patients
-
Growing interest in biomarkers for prognosis and inflammatory response
-
Rapid recovery of diagnostic testing volumes post-pandemic
Deferred cardiac care and post-COVID cardiovascular complications further supported renewed demand for advanced biomarkers.
Global ST2 Biomarker Market Segmentation
By Assay Type
-
ELISA-Based ST2 Assays
-
Immunochromatography-Based (Rapid) ST2 Tests
-
Chemiluminescence Immunoassays (CLIA)
By Test Format
-
Laboratory-Based Tests
-
Point-of-Care (POC) Tests
By Application
-
Heart Failure Diagnosis & Prognosis
-
Risk Stratification & Disease Monitoring
-
Therapy Guidance & Outcome Prediction
-
Research & Clinical Trials
By End User
-
Hospitals
-
Diagnostic & Reference Laboratories
-
Ambulatory Surgical Centers
-
Research Institutes & Academic Centers
Regional Analysis
North America
-
Early adoption of advanced cardiac biomarkers
-
Strong clinical evidence and guideline support
-
High penetration of automated immunoassay platforms
Europe
-
Growing integration of ST2 testing in heart-failure management
-
Strong public healthcare diagnostics infrastructure
-
Rising use in academic and clinical research
Asia-Pacific
-
Fastest-growing regional market
-
Increasing cardiovascular disease burden
-
Expansion of diagnostic laboratory networks
South America
-
Gradual adoption supported by private diagnostics
-
Increasing awareness of biomarker-guided care
Middle East & Africa
-
Growth driven by tertiary hospitals and cardiac centers
-
Improving access to advanced diagnostics
Competitive Landscape – Key Market Players
Competition is shaped by assay accuracy, automation compatibility, regulatory approvals, and clinical validation. Key players operating in the global ST2 biomarker market include:
-
Thermo Fisher Scientific
-
BD
-
Roche
-
Abbott
-
Siemens Healthineers
-
Bio-Rad
-
bioMérieux
-
DiaSorin
-
Randox Laboratories
Porter’s Five Forces Analysis
-
Threat of New Entrants: Medium – assay development and regulatory approval required
-
Bargaining Power of Suppliers: Moderate – reliance on antibodies and reagents
-
Bargaining Power of Buyers: High – hospitals and labs negotiate on price and volume
-
Threat of Substitutes: Moderate – BNP/NT-proBNP and other cardiac biomarkers
-
Competitive Rivalry: High – innovation and automation drive competition
SWOT Analysis
Strengths
-
High prognostic value in heart failure
-
Less biological variability compared to traditional markers
-
Strong clinical evidence base
Weaknesses
-
Limited awareness in some regions
-
Reimbursement variability
Opportunities
-
Expansion of point-of-care testing
-
Integration with multi-biomarker panels
-
Growth in emerging healthcare markets
Threats
-
Competition from established cardiac biomarkers
-
Pricing pressure from healthcare payers
Trend Analysis
-
Increasing adoption of biomarker-guided heart-failure management
-
Growth of automated and high-throughput immunoassays
-
Development of POC and rapid ST2 tests
-
Integration of ST2 with multi-analyte cardiovascular panels
-
Rising use in clinical trials and outcome prediction
Market Drivers & Challenges
Key Drivers
-
Rising global prevalence of heart failure
-
Demand for accurate prognostic biomarkers
-
Shift toward personalized and precision cardiology
Key Challenges
-
Limited clinician awareness in developing markets
-
Reimbursement and cost constraints
-
Competition from conventional biomarkers
Value Chain Analysis
-
Antibody & Reagent Suppliers
-
Diagnostic Kit & Assay Manufacturers
-
Instrument & Automation Providers
-
Hospitals & Diagnostic Laboratories
-
Clinicians & Patients
Strategic Recommendations for Stakeholders
-
Diagnostic Manufacturers: Expand automated and POC ST2 assay portfolios
-
Hospitals & Labs: Integrate ST2 testing into heart-failure care pathways
-
Investors: Focus on Asia-Pacific diagnostics growth and POC technologies
-
Clinicians: Adopt multi-biomarker strategies for risk stratification
-
Policy Makers & Payers: Support reimbursement based on clinical outcome benefits
1. Market Overview of ST2 Biomarker
1.1 ST2 Biomarker Market Overview
1.1.1 ST2 Biomarker Product Scope
1.1.2 Market Status and Outlook
1.2 ST2 Biomarker Market Size by Regions: 2015 VS 2021 VS 2026
1.3 ST2 Biomarker Historic Market Size by Regions
1.4 ST2 Biomarker Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact ST2 Biomarker Sales Market by Type
2.1 Global ST2 Biomarker Historic Market Size by Type
2.2 Global ST2 Biomarker Forecasted Market Size by Type
2.3 ELISA Based ST2 Biomarker
2.4 Immunochromatography Based ST2 Biomarker
3. Covid-19 Impact ST2 Biomarker Sales Market by Application
3.1 Global ST2 Biomarker Historic Market Size by Application
3.2 Global ST2 Biomarker Forecasted Market Size by Application
3.3 Hospitals
3.4 Diagnostic Centres
3.5 Ambulatory Surgical Centres
3.6 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global ST2 Biomarker Production Capacity Market Share by Manufacturers
4.2 Global ST2 Biomarker Revenue Market Share by Manufacturers
4.3 Global ST2 Biomarker Average Price by Manufacturers
5. Company Profiles and Key Figures in ST2 Biomarker Business
5.1 Thermo Fisher Scientific
5.1.1 Thermo Fisher Scientific Company Profile
5.1.2 Thermo Fisher Scientific ST2 Biomarker Product Specification
5.1.3 Thermo Fisher Scientific ST2 Biomarker Production Capacity, Revenue, Price and Gross Margin
5.2 BD
5.2.1 BD Company Profile
5.2.2 BD ST2 Biomarker Product Specification
5.2.3 BD ST2 Biomarker Production Capacity, Revenue, Price and Gross Margin
5.3 Roche
5.3.1 Roche Company Profile
5.3.2 Roche ST2 Biomarker Product Specification
5.3.3 Roche ST2 Biomarker Production Capacity, Revenue, Price and Gross Margin
5.4 Abbott
5.4.1 Abbott Company Profile
5.4.2 Abbott ST2 Biomarker Product Specification
5.4.3 Abbott ST2 Biomarker Production Capacity, Revenue, Price and Gross Margin
5.5 Siemens
5.5.1 Siemens Company Profile
5.5.2 Siemens ST2 Biomarker Product Specification
5.5.3 Siemens ST2 Biomarker Production Capacity, Revenue, Price and Gross Margin
5.6 Bio-Rad
5.6.1 Bio-Rad Company Profile
5.6.2 Bio-Rad ST2 Biomarker Product Specification
5.6.3 Bio-Rad ST2 Biomarker Production Capacity, Revenue, Price and Gross Margin
5.7 BioMerieux
5.7.1 BioMerieux Company Profile
5.7.2 BioMerieux ST2 Biomarker Product Specification
5.7.3 BioMerieux ST2 Biomarker Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America ST2 Biomarker Market Size
6.2 North America ST2 Biomarker Key Players in North America
6.3 North America ST2 Biomarker Market Size by Type
6.4 North America ST2 Biomarker Market Size by Application
7. East Asia
7.1 East Asia ST2 Biomarker Market Size
7.2 East Asia ST2 Biomarker Key Players in North America
7.3 East Asia ST2 Biomarker Market Size by Type
7.4 East Asia ST2 Biomarker Market Size by Application
8. Europe
8.1 Europe ST2 Biomarker Market Size
8.2 Europe ST2 Biomarker Key Players in North America
8.3 Europe ST2 Biomarker Market Size by Type
8.4 Europe ST2 Biomarker Market Size by Application
9. South Asia
9.1 South Asia ST2 Biomarker Market Size
9.2 South Asia ST2 Biomarker Key Players in North America
9.3 South Asia ST2 Biomarker Market Size by Type
9.4 South Asia ST2 Biomarker Market Size by Application
10. Southeast Asia
10.1 Southeast Asia ST2 Biomarker Market Size
10.2 Southeast Asia ST2 Biomarker Key Players in North America
10.3 Southeast Asia ST2 Biomarker Market Size by Type
10.4 Southeast Asia ST2 Biomarker Market Size by Application
11. Middle East
11.1 Middle East ST2 Biomarker Market Size
11.2 Middle East ST2 Biomarker Key Players in North America
11.3 Middle East ST2 Biomarker Market Size by Type
11.4 Middle East ST2 Biomarker Market Size by Application
12. Africa
12.1 Africa ST2 Biomarker Market Size
12.2 Africa ST2 Biomarker Key Players in North America
12.3 Africa ST2 Biomarker Market Size by Type
12.4 Africa ST2 Biomarker Market Size by Application
13. Oceania
13.1 Oceania ST2 Biomarker Market Size
13.2 Oceania ST2 Biomarker Key Players in North America
13.3 Oceania ST2 Biomarker Market Size by Type
13.4 Oceania ST2 Biomarker Market Size by Application
14. South America
14.1 South America ST2 Biomarker Market Size
14.2 South America ST2 Biomarker Key Players in North America
14.3 South America ST2 Biomarker Market Size by Type
14.4 South America ST2 Biomarker Market Size by Application
15. Rest of the World
15.1 Rest of the World ST2 Biomarker Market Size
15.2 Rest of the World ST2 Biomarker Key Players in North America
15.3 Rest of the World ST2 Biomarker Market Size by Type
15.4 Rest of the World ST2 Biomarker Market Size by Application
16 ST2 Biomarker Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Global ST2 Biomarker Market Segmentation
By Assay Type
-
ELISA-Based ST2 Assays
-
Immunochromatography-Based (Rapid) ST2 Tests
-
Chemiluminescence Immunoassays (CLIA)
By Test Format
-
Laboratory-Based Tests
-
Point-of-Care (POC) Tests
By Application
-
Heart Failure Diagnosis & Prognosis
-
Risk Stratification & Disease Monitoring
-
Therapy Guidance & Outcome Prediction
-
Research & Clinical Trials
By End User
-
Hospitals
-
Diagnostic & Reference Laboratories
-
Ambulatory Surgical Centers
-
Research Institutes & Academic Centers
